Petra Alexandra Priemel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Petra Alexandra Priemel has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Rades
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
15 shared publications - Holger Grohganz
Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
11 shared publications - Korbinian Löbmann
Department of Pharmacy, University of Copenhagen, DK-2100 Copenhagen, Denmark
6 shared publications - Clare Joanna Strachan
Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00790 Helsinki, Finland
5 shared publications Riikka Laitinen
University of Eastern Finland
4 shared publications- Hanne Mørck Nielsen
University of Copenhagen
3 shared publications
Latest Publications
- 30 May 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 70 (8) , 1009-1021
Poly(ethylene carbonate)-containing polylactic acid microparticles with rifampicin improve drug delivery to macrophages
Objective Pulmonary delivery of antibiotics will decrease the required dose for efficient treatment of lung infections and reduce systemic side effects of the drug. The objective was to evaluate the applicability of poly(ethylene carbonate) (PEC) for the preparation of inhalable, antibiotic‐containing particles. Methods Rifampicin (RF)‐loaded microparticles were prepared by electrospraying a carrier matrix of polylactic acid (PLA) with 0%, 5% and 10% PEC. Key findings Prepared particles had an aerodynamic diameter between 4 and 5 μm. Within 60 min, PEC‐containing particles released 35–45% of RF, whereas PLA particles released only 15% of RF. Irrespective of particle composition, uptake of RF by macrophages was improved to 40–60% when formulated in microparticles compared to 0.4% for RF in solution, and intracellular localisation of particles was confirmed using confocal microscopy. Effect on macrophage and alveolar cell viability was similar for all particles whereas the minimal inhibitory concentrations against Pseudomonas aeruginosa and Escherichia coli for RF‐containing PEC particles were twofold lower than for PLA particles, explained by the faster release of RF from PEC‐containing particles. Conclusions The inclusion of PEC in PLA microparticles increased the release of RF and the inhibitory effect against two bacteria species while displaying physical particle properties similar to PLA particles.
- 30 May 2018
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 70 (8) , 1009-1021
Poly(ethylene carbonate)-containing polylactic acid microparticles with rifampicin improve drug delivery to macrophages
Objective Pulmonary delivery of antibiotics will decrease the required dose for efficient treatment of lung infections and reduce systemic side effects of the drug. The objective was to evaluate the applicability of poly(ethylene carbonate) (PEC) for the preparation of inhalable, antibiotic‐containing particles. Methods Rifampicin (RF)‐loaded microparticles were prepared by electrospraying a carrier matrix of polylactic acid (PLA) with 0%, 5% and 10% PEC. Key findings Prepared particles had an aerodynamic diameter between 4 and 5 μm. Within 60 min, PEC‐containing particles released 35–45% of RF, whereas PLA particles released only 15% of RF. Irrespective of particle composition, uptake of RF by macrophages was improved to 40–60% when formulated in microparticles compared to 0.4% for RF in solution, and intracellular localisation of particles was confirmed using confocal microscopy. Effect on macrophage and alveolar cell viability was similar for all particles whereas the minimal inhibitory concentrations against Pseudomonas aeruginosa and Escherichia coli for RF‐containing PEC particles were twofold lower than for PLA particles, explained by the faster release of RF from PEC‐containing particles. Conclusions The inclusion of PEC in PLA microparticles increased the release of RF and the inhibitory effect against two bacteria species while displaying physical particle properties similar to PLA particles.
- 1 January 2018
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 122, 62-69
Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin
- 1 January 2018
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 122, 62-69
Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin
- 1 January 2018
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 144, 177-185
Combining diagnostic methods for antimicrobial susceptibility testing – A comparative approach
- 1 January 2018
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 144, 177-185
Combining diagnostic methods for antimicrobial susceptibility testing – A comparative approach
- 1 November 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 533 (1) , 26-33
Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis
- 1 November 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 533 (1) , 26-33
Preparation and investigation of P28GST-loaded PLGA microparticles for immunomodulation of experimental colitis
- Open Access
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 1-12
Supersaturating drug delivery systems: The potential of co-amorphous drug formulations
- 1 October 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 532 (1) , 1-12
Open AccessSupersaturating drug delivery systems: The potential of co-amorphous drug formulations
- 1 April 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 522 (1-2) , 74-79
Amorphous is not always better—A dissolution study on solid state forms of carbamazepine
- 1 April 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 522 (1-2) , 74-79
Amorphous is not always better—A dissolution study on solid state forms of carbamazepine
- 1 March 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 519 (1-2) , 343-351
Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ
- 1 March 2017
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 519 (1-2) , 343-351
Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ
- Open Access
- 9 October 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (10) , 1688
Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches
Bacterial biofilm-associated chronic sinusitis in cystic fibrosis (CF) patients caused by Pseudomonas aeruginosa infections and the lack of available treatments for such infections constitute a critical aspect of CF disease management. Currently, inhalation therapies to combat P. aeruginosa infections in CF patients are focused mainly on the delivery of antimicrobials to the lower respiratory tract, disregarding the sinuses. However, the sinuses constitute a reservoir for P. aeruginosa growth, leading to re-infection of the lungs, even after clearing an initial lung infection. Eradication of P. aeruginosa from the respiratory tract after a first infection has been shown to delay chronic pulmonary infection with the bacteria for up to two years. The challenges with providing a suitable treatment for bacterial sinusitis include: (i) identifying a suitable antimicrobial compound; (ii) selecting a suitable device to deliver the drug to the sinuses and nasal cavities; and (iii) applying a formulation design, which will mediate delivery of a high dose of the antimicrobial directly to the site of infection. This review highlights currently available inhalable antimicrobial formulations for treatment and management of biofilm infections caused by P. aeruginosa and discusses critical issues related to novel antimicrobial drug formulation design approaches.
- 9 October 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (10) , 1688
Open AccessInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches
Bacterial biofilm-associated chronic sinusitis in cystic fibrosis (CF) patients caused by Pseudomonas aeruginosa infections and the lack of available treatments for such infections constitute a critical aspect of CF disease management. Currently, inhalation therapies to combat P. aeruginosa infections in CF patients are focused mainly on the delivery of antimicrobials to the lower respiratory tract, disregarding the sinuses. However, the sinuses constitute a reservoir for P. aeruginosa growth, leading to re-infection of the lungs, even after clearing an initial lung infection. Eradication of P. aeruginosa from the respiratory tract after a first infection has been shown to delay chronic pulmonary infection with the bacteria for up to two years. The challenges with providing a suitable treatment for bacterial sinusitis include: (i) identifying a suitable antimicrobial compound; (ii) selecting a suitable device to deliver the drug to the sinuses and nasal cavities; and (iii) applying a formulation design, which will mediate delivery of a high dose of the antimicrobial directly to the site of infection. This review highlights currently available inhalable antimicrobial formulations for treatment and management of biofilm infections caused by P. aeruginosa and discusses critical issues related to novel antimicrobial drug formulation design approaches.
- 1 May 2016
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 100, 126-132
Unintended and in situ amorphisation of pharmaceuticals
- 1 May 2016
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 100, 126-132
Unintended and in situ amorphisation of pharmaceuticals
- 9 February 2016
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 34, 32-40
Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with Eudragit® E PO
- 9 February 2016
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 34, 32-40
Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with Eudragit® E PO